Articles tagged with Melanoma
A UCLA-led research team has pinpointed a three-drug combination that can effectively treat advanced melanoma. The approach shows promise for extending the lives of people with BRAF V600E mutated melanoma, with progression-free survival lasting an average of 16 months.
Melanoma is a type of skin cancer linked to sun exposure, with common areas affected including face, neck, arms, and torso. Genomic sequencing helps identify markers for diagnosis and treatment, while ABCDE criteria aid in suspicious lesion detection.
Researchers investigated risk factors for melanoma dissemination and the impact of time on distant relapse. The findings provide valuable information for improving melanoma treatment outcomes.
Researchers at CNIO have discovered biomarkers in surgically treated patients' fluid that reveal specific mutations and help determine cancer recurrence risk. The new liquid biopsy technique may enable earlier detection and more targeted treatment for melanoma patients.
A University of Colorado Cancer Center study identifies a possible way to predict which melanomas are hot and cold for immunotherapy. Tumors with specific genetic changes in the NF-kB signaling pathway are more likely to respond to anti-PD1 immunotherapies, suggesting a potential biomarker for treatment prediction.
Researchers have discovered a causal link between the gut microbiome and anti-tumor immunity, identifying key bacterial strains that activate the immune system to slow melanoma growth. The study also reveals the role of unfolded protein response (UPR) in this process, providing potential markers for patient stratification.
Researchers found a promising lead in seriniquone, a natural product isolated from seawater bacteria, to treat melanoma. The compound targets a specific biochemical pathway in melanoma cells and has shown potent activity against the disease.
PET/CT scans can monitor immunotherapy treatment for metastatic melanoma and predict outcome, allowing personalized therapy adjustments. The study demonstrates that FDG PET/CT can accurately assess tumor response to checkpoint inhibitor therapy with ipilimumab.
A study at St. Jude Children's Research Hospital identified MAP3K8 as the most commonly mutated gene in pediatric spitzoid melanoma, driving cancer growth and treatment response. Comprehensive genomic testing revealed novel mutations, including kinase fusions, that may be targeted by precision medicines.
Researchers found that a single dose of PD-1 inhibitor before surgery can lead to complete remission and cancer-free follow-up for more than two years. Immune responses from this therapy can peak within seven days, allowing for earlier guidance on the most effective treatment approach.
A new study by Cancer Research UK found that smokers with melanoma are 40% less likely to survive than non-smokers. Researchers believe smoking may disrupt the immune system's ability to fight cancer.
A recent study discovered similar genetic mutations in humans, dogs, and horses that could lead to new drug targets for a rare form of melanoma. The research compared cancer genomes across species to pinpoint key genes mutated in mucosal melanoma.
Researchers sequenced the genomes of human, canine, and equine mucosal melanoma tumours to identify key genes driving the disease. The study reveals genetic similarities between species, shedding light on why immunotherapies are ineffective for some patients with this rare type of cancer.
A new PET probe targets melanin pigment in skin cancer lesions to improve detection of primary and metastatic melanoma. The probe shows promising results in clinical trials, outperforming existing methods like 18F-FDG PET/CT scans.
A state-by-state analysis reveals that melanoma survival rates differ substantially across the US, with states having more practicing physicians and higher percentage of Caucasians experiencing lower survival rates. The study highlights the need for targeted approaches to improve care and reduce deaths associated with melanoma.
A comprehensive study reveals that p62 protein controls multiple factors involved in melanoma metastasis, indicating a coordinated process. The research also identifies FERMT2 as a marker for poor patient prognosis.
A systematic review of research has concluded that visual inspection alone is not sufficient to diagnose skin cancer accurately. Key findings include the limited effectiveness of smartphone applications in detecting melanomas and the potential benefits of dermoscopy and teledermatology.
Researchers at Johns Hopkins Kimmel Cancer Center found that measuring circulating tumor DNA in blood samples can reveal early stages of cancer growth and spread. The study discovered new treatment options for some patients with melanoma who had mutations not detected by genetic profiling.
Melanoma death rates are increasing globally in men, while stabilizing or decreasing in some countries for women. The study analyzed data from 33 countries and found that melanoma is a significant health issue, with men being more likely to die from the disease.
Zebrafish models have been developed to study the intricate molecular pathways underlying mucosal melanomas. The research identified a previously unrecognized tumor suppressor, SPRED1, and its interplay with oncogene KIT. These findings hold promise for developing precision cancer therapies for this rare and aggressive form of melanoma.
A study of moderately dysplastic moles found that patients who received close observation did not develop melanoma at the site of the excised mole, but had a higher risk of developing melanoma at a separate site. The findings suggest that dysplastic moles are not precursors to melanoma, but rather a risk factor.
Researchers found that immunotherapy is effective in treating metastatic melanoma in individuals with CDKN2A mutations, with nearly two-thirds of patients responding to treatment. The study suggests that tumours with CDKN2A mutations have a larger number of mutations, making them easier to recognise by the immune system.
A phase II study led by the University of Texas MD Anderson Cancer Center found that neoadjuvant combination checkpoint blockade produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery. However, the trial was closed early due to high incidence of side effects.
Researchers identified gene mutations that drive melanoma in dogs, which can inform treatment strategies for both species. The study found mutations in the PTPRJ tumor suppressor gene and cancer-activating mutations in the RAS gene, providing a genetic bridge between canine and human melanoma.
A recent study found that there is a correlation between invisible dark matter particles and melanoma, with 1-10% of diagnoses showing a short periodicity coinciding with the orbital period of Mercury. The research proposes that streaming invisible dark matter may be interacting with the human body.
Researchers aim to develop a blood test to detect and track metastatic melanoma by analyzing circulating tumor DNA in the bloodstream, promising a more precise, individualized, sensitive, and quantifiable approach than current imaging tests.
Mount Sinai researchers discovered a novel epigenetic mechanism causing drug resistance in melanoma patients with BRAF gene mutations. A biomarker called IGFBP2 was also identified, which could benefit from combination therapies that inhibit BRAF and IGFBP2-driven pathways.
A gene expression predictor was developed to indicate whether melanoma patients are likely to respond to immune checkpoint inhibitors, a novel type of immunotherapy. The predictor was accurate across multiple melanoma patient datasets and identified nearly all responders and more than half of non-responders.
A large cohort study found CLL patients have a 600% higher risk of melanoma compared to the general population. Close monitoring for early detection is crucial in managing this skin cancer with targeted therapies.
New research reveals that gyms with tanning beds target people at higher risk of skin cancer, increasing the likelihood of addictive behavior. People who tan in gyms tend to be heavier tanners and more likely to experience addiction.
A world-first study found that regular sunscreen users in childhood reduced their risk of developing melanoma by 40 percent. The study analyzed data from nearly 1700 people and showed that sunscreen use was protective against melanoma in young people under 40 years old.
Checkpoint inhibitors improve median and four-year overall survival rates for melanoma brain metastasis patients by 1.4- and 1.5-fold, respectively, according to a national cohort study published in Cancer Immunology Research.
Checkpoint inhibitors have been shown to double median survival and more than double four-year survival rates for patients with melanoma brain metastases. The study analyzed data from over 1,500 cancer programs, revealing a significant improvement in overall survival.
Skin cancer app studies reveal flaws in technology, including failure to recognize rare cancers and scaly areas. Researchers urge caution when using these apps until adequate validation is achieved.
Researchers discover DNA methylation marker that influences PD-L1 expression on cancer cells, shedding light on why new therapies don't work for some patients. The findings suggest epigenetic therapies could be used in combination with immunotherapy to treat melanoma patients.
A University of Colorado Cancer Center study shows that combining radiosurgery with immunotherapy, especially PD-1 inhibitors, can significantly improve cancer control and overall survival in melanoma patients. The study found that patients treated with anti-PD-1 therapies had a median brain metastasis-free survival of not reached, whe...
A recent study published in Clinical Cancer Research found that older melanoma patients are more likely to respond to anti-PD1 immunotherapy compared to younger patients. Researchers analyzed data from 538 patients with melanoma treated with pembrolizumab and found a 13% decrease in progression rates for each decade of life.
The ILLUMINATE-204 trial shows an overall response rate of 38% with 2 complete responses, suggesting a promising strategy for treating patients with metastatic melanoma unresponsive to PD-1 therapy. The combination regimen is generally well-tolerated, with fewer than a quarter of patients experiencing immune-related toxicities.
A deep learning convolutional neural network (CNN) outperforms experienced dermatologists in diagnosing skin cancer, detecting 95% of melanomas at level I. The CNN's performance improves with additional clinical information, highlighting its potential as an aid for physicians.
Research presented at the European Congress on Obesity shows that obesity surgery is associated with a 61% fall in malignant melanoma risk and a 42% drop in skin cancer risk. The study suggests that weight loss in individuals with obesity can reduce the risk of deadly melanoma, which has steadily increased in many countries.
Researchers aim to develop a virtual biopsy tool that can guide patient care without the need for invasive skin cuts. The technology uses multiphoton microscopy and machine learning techniques to provide high-quality images of melanin, enabling doctors to diagnose melanoma more accurately.
A team of melanoma experts at Moffitt's Center of Excellence will investigate the causes and drivers of acral melanoma, a rare form of skin cancer affecting African-Americans. The three-year grant aims to develop better prevention and treatment strategies for this aggressive disease.
A new study found that daily aspirin use is associated with a nearly double risk of melanoma in men compared to those who do not take aspirin. In contrast, women taking daily aspirin did not have an increased risk of melanoma. Researchers suggest increasing patient education about sun exposure and skin checks for high-risk individuals.
A USC study reveals teenage minorities in Los Angeles are struggling with tanning addiction, associated with marijuana abuse and obsessive-compulsive disorder. The condition is more prevalent among Native Hawaiian and Pacific Islanders, highlighting the need for targeted education and services.
A combination of XL888, a HSP90 inhibitor, and vemurafenib, a BRAF inhibitor, was found to be safe and effective in treating advanced melanoma patients, with 75% experiencing a response. The treatment resulted in manageable toxicities and durable responses.
Researchers found that married patients with melanoma are more likely to present with early-stage tumors and undergo sentinel lymph node biopsies, leading to better patient outcomes. The study analyzed over 52,000 patients with no distant metastases from 2010 to 2014.
Researchers identified a novel therapeutic vulnerability in NRAS mutant melanoma, using a combination of BET and MEK inhibitors. The combination treatment showed potent anti-tumor effects and prolonged survival in mice with melanoma resistant to targeted therapies and immunotherapies.
Researchers at University of Texas M. D. Anderson Cancer Center discovered a rare pre-existing mutation in PIK3CA that causes rapid drug resistance in melanoma patients. The study found that this mutation was present in the tumor before treatment and rapidly expanded after treatment, leading to swift disease progression.
Researchers found that repurposed leukemia drugs can inhibit the secretion of pro-metastatic cathepsins in melanoma. This is due to ABL kinases increasing activity, which regulates transcription factors and induces gene expression. The study also showed that approved leukemia drug inhibitors prevent metastasis.
Research finds obese male patients treated with targeted or immune therapies live significantly longer than those with a normal BMI. The 'Obesity Paradox' suggests that obesity may improve survival in men with metastatic melanoma, contradicting prior assumptions about the impact of weight on cancer outcomes.
Researchers from Saarland University conducted a systematic meta-analysis of studies on sunbed use and malignant melanoma. While they found an association between the two, they identified significant methodological shortcomings in earlier studies. Moderate solarium use was not shown to increase the risk of malignant melanoma.
Researchers found that patients who received a combination of BRAF and MEK inhibitors before and after surgery had a six-fold increase in time to progression compared to standard-of-care surgery. The study suggests that presurgical targeted therapy may improve outcomes for patients with high-risk stage 3 melanoma.
Researchers at the University of Pennsylvania have identified a new therapeutic target for melanoma, G protein-coupled estrogen receptor (GPER), which shows promise in combination with anti-PD-1 inhibitors. Activation of GPER may explain why women who have been pregnant have better survival outcomes when facing deadly skin cancer.
Researchers at Penn State found that melanoma patients who received immunotherapy with beta blockers lived significantly longer than those without, with five years survival rates of 70% vs. 25%. The study suggests reducing physiological stress with beta blockers can improve the effectiveness of immunotherapy.
Researchers at the University of East Anglia have discovered that combining an immunosuppressive arthritis drug, leflunomide, with a melanoma treatment may enhance its effectiveness. The study found that the combination almost completely stopped the growth of a melanoma tumor in mice.
A recent study examined the skin cancer history and habits of active Florida firefighters. The research found that 4.5% of participants had skin cancer, with a significantly higher frequency of melanoma (0.7%) compared to the general U.S. population. Non-work-related sun exposure may be contributing to this increased risk.
Researchers at Georgia State University have developed a blood test that can diagnose two types of cancer, lymphoma and melanoma, using mid-infrared spectroscopy. The test has shown promising results in differentiating between healthy mice and those with tumorous conditions, and could potentially be used for screening humans.
A study from Karolinska Institutet found that family members without an inherited CDKN2A mutation still have a higher risk of developing melanoma. This phenomenon, called phenocopy, is attributed to other risk-modifying genes or environmental factors within the families.
A novel compound omaveloxolone has been shown to restore immune response in patients with melanoma, improving antitumour responses when combined with checkpoint inhibitors. The study found a 57% overall response rate in patients who had not received prior checkpoint inhibitor treatment.
A study by UMMS researchers has identified a protein called GDF6 as a primary role in metastatic melanoma, found to be expressed in 80% of human melanomas and correlated with increased melanoma growth and spread. The findings offer new therapeutic potential for treatment-resistant skin cancer.